Skip to main content

Amylyx Pharmaceuticals, Inc.

corporate_fare Company Profile

Amylyx Pharmaceuticals, Inc.

AMLX·NASDAQ·Life Sciences·CIK 0001658551

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing new therapies for communities with significant unmet medical needs. The company has preclinical and clinical development programs in both endocrine conditions and neurodegenerative diseases. Amylyx's lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been studied as a treatment for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (Congenital HI), both conditions characterized by hyperinsulinemic hypoglycemia. The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both PBH and HI, Rare Pediatric Disease Designation in Congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia. Post-bariatric hypoglycemia (PBH) is a condition estimated to affect approximately 8% of people in the U.S. who have undergone sleeve gastrectomy and Roux-en-Y gastric bypass, which is about 160,000 people in the U.S. This condition is believed to result from an excessive GLP-1 response, leading to low blood sugar (hypoglycemia) and reduced quality of life. PBH can cause severe hypoglycemic events where the brain doesn't get enough glucose, potentially leading to impaired thinking, loss of consciousness, and seizures. PBH is also linked to significant disability that can disrupt independent living. Currently, there are no approved therapies for PBH. Avexitide is designed to attach to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of GLP-1 to reduce hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for AMLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AMLX spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Amylyx Q3 Loss Widens to $45.5M as Avexitide Launch Prep Drives Spend; $768.1M Cash
  • Amylyx Secures Long-Term Avexitide Manufacturing with Bachem and Polypeptide
  • Amylyx Formalizes $500M Upsized Offering: $471.7M Net Proceeds, Closing August 21
  • Amylyx Prices Upsized $500M Offering at $35.50 After Avexitide Win
  • Amylyx Upsizes Offering to $500M After Avexitide Win, Pricing at $35.50

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$144.74M
Diluted EPS
-$1.53
Op. Cash Flow
-$123.34M
Free Cash Flow
-$123.48M
Gross Profit
$0
Operating Income
-$153.29M
Cash & Equivalents
$226.65M
Debt / Equity
0.00×
Shares Outstanding
109.88M sh
Source: 10-K · filed 2026-03-03 · accession 0001193125-26-086645

Short Interest & Short Volume

10.47 days to cover

FINRA reported short interest of 12,823,384 shares in AMLX as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of AMLX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,823,384 shares as of October 30, 2026
Change vs prior period▼ 3.2%
Days to cover10.47 at avg daily volume of 1,224,774
Daily short volume (FINRA facilities)54.3% of 400,145 shares on November 20, 2026
5-day average short volume58.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AMLX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.

1 recent capital raise

Offering Upsized to $500M · Dilution of ~12.7%

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$25.55 -1.81% today
52-week range · as of 2026-11-05 $10.83 – $41.14
Market cap
$3.35B
Volume
1.1M (0.8× avg)
3-mo avg 1.4M
Live data · 2026-11-21 09:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AMLX - Latest Insights

AMLX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $25.55 info
Change: -$4.45 (-15%) info
Market Cap: $3.345B info
AMLX
Sep 08, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.88
Real-time Price: $25.55 info
Change: -$8.33 (-25%) info
Market Cap: $3.345B info
AMLX
Aug 20, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $25.55 info
Change: -$14.16 (-36%) info
Market Cap: $3.345B info
AMLX
Aug 20, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $25.55 info
Change: -$14.16 (-36%) info
Market Cap: $3.345B info
AMLX
Aug 19, 2026, 11:06 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $38.45
Real-time Price: $25.55 info
Change: -$12.90 (-34%) info
Market Cap: $3.345B info
AMLX
Aug 19, 2026, 4:36 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $35.10
Real-time Price: $25.55 info
Change: -$9.55 (-27%) info
Market Cap: $3.345B info
AMLX
Aug 18, 2026, 5:17 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $35.50
Real-time Price: $25.55 info
Change: -$9.95 (-28%) info
Market Cap: $3.345B info
AMLX
Aug 18, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $35.08
Real-time Price: $25.55 info
Change: -$9.53 (-27%) info
Market Cap: $3.345B info
AMLX
Aug 18, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.01
Real-time Price: $25.55 info
Change: -$3.46 (-12%) info
Market Cap: $3.345B info
AMLX
Aug 18, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $26.00
Real-time Price: $25.55 info
Change: -$0.450 (-2%) info
Market Cap: $3.345B info
AMLX
Aug 18, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $26.00
Real-time Price: $25.55 info
Change: -$0.450 (-2%) info
Market Cap: $3.345B info
AMLX
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $23.25
Real-time Price: $25.55 info
Change: +$2.30 (+10%) info
Market Cap: $3.345B info
AMLX
Aug 06, 2026, 7:26 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $21.61
Real-time Price: $25.55 info
Change: +$3.94 (+18%) info
Market Cap: $3.345B info
AMLX
Aug 06, 2026, 7:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $21.60
Real-time Price: $25.55 info
Change: +$3.95 (+18%) info
Market Cap: $3.345B info
AMLX
May 07, 2026, 7:04 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.51
Real-time Price: $25.55 info
Change: +$9.04 (+55%) info
Market Cap: $3.345B info
AMLX
May 07, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.51
Real-time Price: $25.55 info
Change: +$9.04 (+55%) info
Market Cap: $3.345B info
AMLX
Apr 23, 2026, 7:01 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $17.46
Real-time Price: $25.55 info
Change: +$8.09 (+46%) info
Market Cap: $3.345B info
AMLX
Mar 24, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.30
Real-time Price: $25.55 info
Change: +$11.25 (+79%) info
Market Cap: $3.345B info
AMLX
Mar 03, 2026, 7:10 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $25.55 info
Change: +$10.55 (+70%) info
Market Cap: $3.345B info
AMLX
Mar 03, 2026, 7:08 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $25.55 info
Change: +$10.55 (+70%) info
Market Cap: $3.345B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets